Xenetic Biosciences Inc
$ 3.06
-2.86%
10 Apr - close price
- Market Cap 7,010,600 USD
- Current Price $ 3.06
- High / Low $ 3.18 / 3.05
- Stock P/E N/A
- Book Value 3.23
- EPS -1.58
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -0.40 %
- 52 Week High 13.93
- 52 Week Low 1.90
About
Xenetic Biosciences, Inc., a biopharmaceutical company, is focused on advancing XCART, a customized chimeric antigen receptor T (CAR T) platform technology designed to target patient-specific tumor neoantigens. The company is headquartered in Framingham, Massachusetts.
Analyst Target Price
$40.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-25 | 2025-11-12 | 2025-08-12 | 2025-05-07 | 2025-03-19 | 2024-11-07 | 2024-08-09 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -0.22 | -0.33 | -0.45 | -0.59 | -0.68 | -0.28 | -0.83 | -0.78 | -0.77 | -0.69 | -0.69 | -0.6 |
| Estimated EPS | -0.52 | -0.84 | -0.79 | -0.72 | -0.2 | -0.14 | -0.83 | -0.79 | -0.87 | -1.12 | -1.13 | -1.1 |
| Surprise | 0.3 | 0.51 | 0.34 | 0.13 | -0.48 | -0.14 | 0 | 0.01 | 0.1 | 0.43 | 0.44 | 0.5 |
| Surprise Percentage | 57.6923% | 60.7143% | 43.038% | 18.0556% | -240% | -100% | 0% | 1.2658% | 11.4943% | 38.3929% | 38.9381% | 45.4545% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XBIO
2026-04-04 11:10:29
This article provides details on the Price-to-Book (PB) Ratio for Xenetic Biosciences (XBIO.WS) as of April 5, 2026. It defines the PB Ratio, explains its calculation, and discusses its applicability, noting it's best for asset-heavy businesses like banks. The article also mentions that Xenetic Biosciences's current PB Ratio is not ranked in its industry due to a book value of $0.00 per share.
2026-03-14 11:38:50
Xenetic Biosciences, Inc. announced its full-year 2025 financial results, highlighting encouraging preclinical and translational data for its DNase-based technology aimed at difficult-to-treat cancers. The company continued advancing its DNase technology towards Phase 1 clinical development and ended the year with $9.8 million in cash. Net loss for 2025 was approximately $8.5 million, while royalty revenue increased by 19% to $3.0 million.
2026-03-13 15:51:49
Xenetic Biosciences, Inc. reported its full-year 2025 financial results, highlighting progress in its DNase-based immuno-oncology technology with encouraging preclinical data and advancement toward IND-enabling activities. The company ended the year with $7.9 million in cash, supported by a public offering, and reported a net loss of $2.7 million for the year. Xenetic is pursuing strategic alternatives to maximize shareholder value while continuing to focus on its systemic DNase program for difficult-to-treat cancers.
2026-03-13 15:51:49
Xenetic Biosciences, Inc. reported its full-year 2025 financial results, including a net loss of $2.7 million as it continued to invest in its DNase-based immuno-oncology programs. The company highlighted encouraging preclinical data, progress in investigator-initiated studies, and advancements toward IND-enabling activities for its DNase I program. Xenetic ended 2025 with $7.9 million in cash, supported by a public offering, maintaining a strategic focus on its innovative approach to difficult-to-treat cancers.
2026-03-13 12:52:56
Xenetic Biosciences (XBIO) has reported an increase in revenue to $2.98 million and is making progress in advancing its DNase-based technology towards Phase 1 clinical trials. The company emphasizes disciplined capital use and strategic positioning for the upcoming year, despite facing challenges in profitability with negative operating and net margins. While Xenetic shows strong financial strength with no debt and high liquidity, its valuation metrics suggest potential undervaluation, and an Altman Z-Score in the distress zone indicates a potential risk of bankruptcy.
2026-03-13 12:39:31
Xenetic Biosciences (XBIO) reported a 19% increase in revenue to $3.0M, driven by higher royalties, while its net loss narrowed to $2.7M. The company is advancing its DNase technology in oncology with funding from a $4M public offering and is currently undergoing a strategic review to explore potential transactions. This update highlights their financial performance and strategic direction in the biotech sector.
